Fedora Pharmaceuticals Inc.

Canada

Back to Profile

1-16 of 16 for Fedora Pharmaceuticals Inc. Sort by
Query
Aggregations
Jurisdiction
        United States 12
        World 3
        Canada 1
Date
2023 3
2022 2
Before 2020 10
IPC Class
C07D 471/08 - Bridged systems 13
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine 11
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems 8
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin 7
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol 7
See more
Status
Pending 2
Registered / In Force 14
Found results for  patents

1.

LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS

      
Application Number 18225859
Status Pending
Filing Date 2023-07-25
First Publication Date 2023-11-23
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Jankowska, Renata
  • Salama, Sameeh M.
  • Maiti, Samarendra N.

Abstract

Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with β-lactamase inhibitors and/or additional antibiotics (including β-lactam and non-β-lactam antibiotics) in the treatment or prevention of bacterial infections.

IPC Classes  ?

  • C07D 471/04 - Ortho-condensed systems
  • C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • C07D 487/04 - Ortho-condensed systems
  • C07D 493/08 - Bridged systems
  • C07D 471/08 - Bridged systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • C07D 513/04 - Ortho-condensed systems
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

2.

PHARMACEUTICAL COMPOSITIONS COMPRISING LTV-17 AND BETA-LACTAMASE INHIBITORS AND THEIR USE AS ANTIBACTERIAL AGENTS

      
Application Number IB2022060852
Publication Number 2023/084455
Status In Force
Filing Date 2022-11-10
Publication Date 2023-05-19
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Salama, Sameeh M.
  • Maiti, Samarendra N.
  • Jankowska, Renata

Abstract

Pharmaceutical combinations comprising a lactivicin such as L TV-17 of formula (I) and one or more beta-lactamase inhibitors such as avibactam are disclosed. Lactivicin L TV-17 in combination with the beta lactamase inhibitor avibactam are disclosed as synergistic against various bacterial strains. The combinations are used in methods to treat or prevent bacterial infection.

IPC Classes  ?

  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
  • A61K 31/69 - Boron compounds
  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61P 31/04 - Antibacterial agents
  • C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • C07D 471/08 - Bridged systems
  • C07D 471/18 - Bridged systems
  • C07D 499/86 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penemsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
  • C07D 499/87 - Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
  • C07D 503/18 - Radicals substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical by oxygen atoms
  • C07F 5/02 - Boron compounds

3.

Pharmaceutical compositions comprising LTV-17 and beta-lactamase inhibitors and their use as antibacterial agents

      
Application Number 17984553
Grant Number 11998533
Status In Force
Filing Date 2022-11-10
First Publication Date 2023-05-18
Grant Date 2024-06-04
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Salama, Sameeh M.
  • Maiti, Samarendra N.
  • Jankowska, Renata

Abstract

Pharmaceutical combinations of LTV-17 (I), a lactivicin derivative, and β-lactamase inhibitors are provided, wherein the combinations comprise antibacterial agents suitable for use in the treatment or prevention of bacterial infections.

IPC Classes  ?

  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
  • A61P 31/04 - Antibacterial agents

4.

Lactivicin compounds, their preparation and use as antibacterial agents

      
Application Number 17707297
Grant Number 11780832
Status In Force
Filing Date 2022-03-29
First Publication Date 2022-10-13
Grant Date 2023-10-10
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Jankowska, Renata
  • Salama, Sameeh M.
  • Maiti, Samarendra N.

Abstract

Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with β-lactamase inhibitors and/or other antibiotics (including β-lactam and non-β-lactam antibiotics) in the treatment or prevention of bacterial infections.

IPC Classes  ?

  • C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • C07D 471/04 - Ortho-condensed systems
  • C07D 487/04 - Ortho-condensed systems

5.

LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS

      
Application Number IB2022052900
Publication Number 2022/208356
Status In Force
Filing Date 2022-03-29
Publication Date 2022-10-06
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Jankowska, Renata
  • Salama, Sameeh M.
  • Maiti, Samarendra N.

Abstract

Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with P-lactamase inhibitors and/or other antibiotics (including P-lactam and non-P-lactam antibiotics) in the treatment or prevention of bacterial infections.

IPC Classes  ?

  • C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • A61K 31/04 - Nitro compounds
  • A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
  • A61K 31/69 - Boron compounds
  • A61K 31/424 - Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/428 - Thiazoles condensed with carbocyclic rings
  • A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
  • A61K 31/433 - Thiadiazoles
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • C07D 471/04 - Ortho-condensed systems
  • C07D 471/08 - Bridged systems
  • C07D 471/18 - Bridged systems
  • C07D 487/04 - Ortho-condensed systems
  • C07D 499/86 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penemsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
  • C07D 503/18 - Radicals substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical by oxygen atoms
  • C07F 5/02 - Boron compounds

6.

Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof

      
Application Number 16140597
Grant Number 10584123
Status In Force
Filing Date 2018-09-25
First Publication Date 2019-04-11
Grant Date 2020-03-10
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Kammerer, Michael
  • Ran, Frédéric

Abstract

The present invention relates to a process for producing crystalline and amorphous forms of a diazabicyclooctane derivative represented by Compound (I) and methods for producing the same.

IPC Classes  ?

  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • C07D 471/08 - Bridged systems
  • A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

7.

Crystalline forms of diazabicyclooctane derivatives and production process thereof

      
Application Number 16140601
Grant Number 10759800
Status In Force
Filing Date 2018-09-25
First Publication Date 2019-03-28
Grant Date 2020-09-01
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Kammerer, Michael
  • Ran, Frederic

Abstract

The present invention relates to crystalline forms of a diazabicyclooctane derivative represented by Compound I, the process for producing the same and methods for using the same:

IPC Classes  ?

8.

Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same

      
Application Number 16140608
Grant Number 10682413
Status In Force
Filing Date 2018-09-25
First Publication Date 2019-03-28
Grant Date 2020-06-16
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor Yang, Kewei

Abstract

The present invention relates to a pharmaceutical composition and a lyophilisate of a diazabicyclooctane derivative represented by Compound I, a process for producing the same and methods for using the same.

IPC Classes  ?

  • A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 9/19 - Particulate form, e.g. powders lyophilised

9.

Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors

      
Application Number 16021551
Grant Number 10544146
Status In Force
Filing Date 2018-06-28
First Publication Date 2018-10-25
Grant Date 2020-01-28
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Maiti, Samarendra N.
  • Nguyen, Dai
  • Khan, Jehangir
  • Ling, Rong

Abstract

A compound of formula (I): 3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

IPC Classes  ?

  • C07D 471/08 - Bridged systems
  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
  • C07D 451/06 - Oxygen atoms
  • A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

10.

Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors

      
Application Number 15171237
Grant Number 10030019
Status In Force
Filing Date 2016-06-02
First Publication Date 2016-10-13
Grant Date 2018-07-24
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Maiti, Samarendra N.
  • Nguyen, Dai
  • Khan, Jehangir
  • Ling, Rong

Abstract

A compound of formula (I): 3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

IPC Classes  ?

  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • C07D 471/08 - Bridged systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
  • C07D 451/06 - Oxygen atoms
  • A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

11.

Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors

      
Application Number 14300493
Grant Number 09505761
Status In Force
Filing Date 2014-06-10
First Publication Date 2014-09-25
Grant Date 2016-11-29
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Maiti, Samarendra N.
  • Nguyen, Dai
  • Khan, Jehangir
  • Ling, Rong

Abstract

New bicyclic compounds, their preparation, and their use as antibacterial agents, either alone or in combination with an antibiotic for the treatment of infections caused by β-lactamase-producing pathogenic bacteria, are described.

IPC Classes  ?

  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • C07D 471/08 - Bridged systems
  • C07D 451/06 - Oxygen atoms
  • A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

12.

Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors

      
Application Number 14253085
Grant Number 09393239
Status In Force
Filing Date 2014-04-15
First Publication Date 2014-08-07
Grant Date 2016-07-19
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Maiti, Samarendra N.
  • Nguyen, Dai
  • Khan, Jehangir
  • Ling, Rong

Abstract

A compound of formula (I): 3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

IPC Classes  ?

  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • C07D 471/08 - Bridged systems
  • A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • C07D 451/06 - Oxygen atoms

13.

NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

      
Application Number IB2012002675
Publication Number 2014/091268
Status In Force
Filing Date 2012-12-11
Publication Date 2014-06-19
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Maiti, Samarendra N.
  • Nguyen, Dai
  • Khan, Jehangir
  • Ling, Rong

Abstract

A compound of formula (I), wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1,R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

IPC Classes  ?

  • C07D 471/08 - Bridged systems
  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
  • A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

14.

Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors

      
Application Number 13917932
Grant Number 08877743
Status In Force
Filing Date 2013-06-14
First Publication Date 2013-10-24
Grant Date 2014-11-04
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Maiti, Samarendra N.
  • Nguyen, Dai
  • Khan, Jehangir
  • Ling, Rong

Abstract

A compound of formula (I): 1 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

IPC Classes  ?

  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • C07D 471/08 - Bridged systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
  • C07D 451/06 - Oxygen atoms

15.

Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors

      
Application Number 13690398
Grant Number 08796257
Status In Force
Filing Date 2012-11-30
First Publication Date 2013-08-29
Grant Date 2014-08-05
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Maiti, Samarendra N.
  • Nguyen, Dai
  • Khan, Jehangir
  • Ling, Rong

Abstract

A compound of formula (I): 3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

IPC Classes  ?

  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • C07D 471/08 - Bridged systems

16.

LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS

      
Document Number 03213971
Status Pending
Filing Date 2022-03-29
Grant Date 2025-10-28
Owner FEDORA PHARMACEUTICALS INC. (Canada)
Inventor
  • Jankowska, Renata
  • Salama, Sameeh M.
  • Maiti, Samarendra N.

Abstract

ABSTRACT Lactivicin compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof are provided: (I) These compounds comprise improved antibacterial activity and can be used either alone or in combination with P-lactamase inhibitors and/or other antibiotics (including P -lactam and non- P - lactam antibiotics) in the treatment or prevention of bacterial infections. Date Reçue/Date Received 2024-03-15

IPC Classes  ?

  • A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
  • A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
  • C07D 471/04 - Ortho-condensed systems
  • C07D 471/08 - Bridged systems
  • C07D 471/18 - Bridged systems
  • C07D 487/04 - Ortho-condensed systems
  • C07D 499/86 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penemsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
  • C07D 503/18 - Radicals substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical by oxygen atoms
  • C07F 5/02 - Boron compounds